Raglan Pharmaceutical & Life Science Projects

Raglan Capital is involved as founder or co-founder in a number of pharmaceutical and life science ventures including Amryt Pharma plc, and Open Orphan.

Open Orphan

Open Orphan is building a leading European rare disease and orphan drug focused pharma services company.  The company is a Clinical Research Organisation (CRO) & consulting house focusing on bringing US registered Orphan Products to Europe and driving new research for new rare disease treatments (Orphan Products) in association with Pharma companies. Open Orphan is led by an experienced Board and management team with expertise in orphan drug regulatory approval, market access and reimbursement, commercialisation and launch optimisation. The company’s first goal is to consolidate the market by acquiring a series of smaller European orphan drug companies. Additionally, Open Orphan is developing and deploying a new digital platform to support companies in research & development and commercialization.

Open Orphan is a publicly traded company on the London AIM and Euronext Growth stock exchanges under the symbol ORPH. The company was created in-house by Raglan, following the success and learnings of our first life science project, Amryt Pharma plc. The European Orphan/Rare Disease and Specialty Pharma sector has been chronically underserved and unexploited for the past decade and presents enormous opportunities for Open Orphan to establish itself as a leading player in the space.

Many mid-size and smaller North American pharma companies have tended to overlook or avoid the European market for Orphan/Rare Diseases as they see it as far more complex and difficult than the North American market.

Open Orphan currently has four operating wings that offer a wide range of services.

– Open Orphan Genomic Health Data Platform is building the first European people-powered health data and genomic data collection platform which will allow us to quickly become one of the leading brokers of rare disease patient data.

– Open Orphan Virtual Rep aims to challenge the traditional pharmaceutical commercialisation model by efficiently enabling pharmaceutical companies to engage key opinion leaders (KOLs) and physicians using remote engagement.

– Venn Life Sciences is an Integrated Drug Development Partner offering a unique combination of drug development expertise and clinical trial design and management to pharmaceutical, biotechnology and medical device organisation.

–  hVIVO is an industry-leading clinical development services business pioneering human disease models based upon viral challenge. Using human challenge studies to establish early proof-of-concept, hVIVO’s clinical trial platform can accelerate drug and vaccine development in respiratory and infectious disease.

In a very short period of time Open Orphan has assembled a small team with deep orphan drug/rare disease knowledge and capability and has built the in-house capability to in-licence, get EMA approval, launch and commercialise orphan/rare disease and specialty drugs. We also have extensive capital market, fundraising and IPO experience and capability.

Open Orphan can be found on www.openorphan.com

Amryt Pharmaceuticals

Amryt is a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare or orphan diseases.

Lojuxta is an approved treatment for adult patients with the rare cholesterol disorder – Homozygous Familial Hypercholesterolaemia (“HoFH”). This disorder impairs the body’s ability to remove low density lipoprotein (“LDL”) cholesterol (“bad” cholesterol) from the blood, typically leading to abnormally high blood LDL cholesterol levels in the body and subsequent aggressive and premature narrowing and blocking of blood vessels.  Lojuxta is indicated as an adjunct to a low-fat diet and other lipid-lowering medicinal products with or without LDL apheresis in adult patients with HoFH.

Amryt holds an exclusive licence to sell Lojuxta (lomitapide) across the European Economic Area, Middle East and North Africa, Switzerland, Turkey, Israel, Russia, the Commonwealth of Independent States and the non-EU Balkan states.

Amryt’s lead drug candidate, AP101, is a potential treatment for Epidermolysis Bullosa (“EB”), a rare and distressing genetic skin disorder affecting young children for which there is currently no treatment.  It is currently in Phase 3 clinical trials. The European and US market opportunity for EB is estimated to be in excess of €1.3 billion.

Amryt’s earlier stage product AP102 is focused on developing novel, next generation somatostatin analogue (“SSA”) peptide medicines for patients with rare neuroendocrine diseases, where there is a high unmet medical need, including acromegaly and Cushing’s disease.

In March 2018, Amryt in-licensed a pre-clinical gene-therapy platform technology, AP103, which offers a potential treatment for patients with Recessive Dystrophic Epidermolysis Bullosa, a subset of EB, and is also potentially relevant to other genetic disorders.

For more information on Amryt, please visit amrytpharma.com